ALLR (Allarity Therapeutics) ROE % Adjusted to Book Value: -52.76% (As of Mar. 2026)


ALLR Allarity Therapeutics Inc ALLR
24 GF Score
Price $1.30
! 2 Warning Signs
View Full Analysis

What is Allarity Therapeutics ROE % Adjusted to Book Value?

Allarity Therapeutics ALLR +1.56% 24 ROE % Adjusted to Book Value is -52.76% as of Mar. 2026. GuruFocus rates ALLR with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

Allarity Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -131.36%. Allarity Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 2.49. Allarity Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -52.76%.

Allarity Therapeutics ROE % Adjusted to Book Value Related Terms

Allarity Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Allarity Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allarity Therapeutics ROE % Adjusted to Book Value Chart

Allarity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 0.00 0.00 -751.63 -58.64

Allarity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -84.36 -49.74 -43.79 -69.81 -52.76

ALLR vs OTLC, MRKR, SKYE: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Allarity Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allarity Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allarity Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Allarity Therapeutics's ROE % Adjusted to Book Value falls into.


ALLR
24GF Score
Allarity Therapeutics Inc ALLR
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Allarity Therapeutics ROE % Adjusted to Book Value Calculation

Allarity Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-103.80% / 1.77
=-58.64%

Allarity Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-131.36% / 2.49
=-52.76%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -52.76% mean?
Allarity Therapeutics (ALLR) has a ROE % Adjusted to Book Value of -52.76% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Allarity Therapeutics and its competitors.
Is Allarity Therapeutics' ROE % Adjusted to Book Value too high?
Allarity Therapeutics' current ROE % Adjusted to Book Value is -52.76%. Overall, Allarity Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Allarity Therapeutics' ROE % Adjusted to Book Value compare to OTLC and MRKR?
Allarity Therapeutics' ROE % Adjusted to Book Value of -52.76% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Allarity Therapeutics and its competitors. Allarity Therapeutics's current ROE % Adjusted to Book Value is -52.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allarity Therapeutics stock overvalued right now?
Allarity Therapeutics (ALLR) has a current ROE % Adjusted to Book Value of -52.76%. The current ROE % Adjusted to Book Value is -52.76%. Allarity Therapeutics' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Allarity Therapeutics (ALLR), the current ROE % Adjusted to Book Value is -52.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allarity Therapeutics Business Description

Address 123 East Tarpon Avenue, Tarpon Springs, FL, USA, 34689
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
24GF Score

Get the complete analysis for ALLR

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.30
Price